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Abstract
Background: We have previously derived highly similar lineage-restricted stem cell lines, RoSH
and E-RoSH cell lines from mouse embryos and CD9hi SSEA-1- differentiated mouse embryonic
stem cells, respectively. These cell lines are not pluripotent and differentiate readily into endothelial
cells in vitro and in vivo.
Results: We investigated the signaling pathway that maintains proliferation of these cells in an
undifferentiated state, and demonstrate that PI3 K/Akt/mTOR, but not Raf/MEK/Erk, signaling in
these cells was active during proliferation and was downregulated during endothelial differentiation.
Inhibition of PI3 K/Akt/mTOR signaling, but not Raf/MEK/Erk, reduced proliferation and induced
expression of endothelial specific proteins. During differentiation or inhibition of PI3 K/Akt/mTOR
signaling, cyclinD2 transcript abundance in ribosome-enriched RNA but not in total RNA was
reduced with a corresponding reduction in protein level. In contrast, transcript abundance of
endothelial-specific genes e.g. Kdr, Tek and Pdgfrα in ribosome-enriched RNA fraction was not
reduced and their protein levels were increased. Together these observations suggested that
translational control mediated by PI3K/Akt/mTOR signaling was critical in regulating proliferation
and endothelial differentiation of lineage-restricted RoSH-like stem cell lines.
Conclusion: This study highlights translation regulation as a critical regulatory mechanism during
proliferation and differentiation in stem cells.
Background
Embryonic stem cells (ESCs) are pluripotent stem cells
capable of differentiating into cells of all three germ lay-
ers, making ESCs an ideal source of cells for regenerative
therapy for many diseases and tissue injuries [1,2]. How-
ever, this property of ESCs poses a unique challenge of
having to generate therapeutically efficacious quantity of
appropriate cell types without being contaminated by
potentially deleterious cell types. Recently, we have gener-
ated lineage-restricted stem cell lines with endothelial
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potential termed RoSH and E-RoSH lines from mouse
embryos and mouse ESCs (mESCs), respectively [3,4].
RoSH and E-RoSH lines are derived from CD9hi, SSEA-1-
cells in embryo and ESC-derived embryoid body cultures.
Despite their different tissue source of origin, both RoSH
and E-RoSH cell lines are highly similar with an almost
identical gene expression profile [3,4]. They differentiate
efficiently into endothelial cells when plated on matrigel
or when transplanted into appropriate animal models.
They can be propagated in culture as cell lines and have a
population doubling time of 12–15 hours. They are also
highly amendable to subcloning from single cells. As ther-
apeutic agents, such cell lines will have several distinct
advantages over pluripotent ESCs. One, they are not
pluripotent and therefore, cannot form teratoma. Two,
these lines as a consequence of their reduced potency dif-
ferentiate efficiently into their target cells, specifically
endothelial cells and formed vascular structures in vitro
and in vivo. Third, as clonable cell lines, these cells can be
produced as highly homogenous cell population on a
large scale.
To better understand and manipulate proliferation and
differentiation of these cell lines, we here investigated two
major signaling pathways known to regulate cellular pro-
liferation, PI3 K/Akt/mTOR [5] and Raf/MEK/Erk [6] in a
representative RoSH/E-RoSH cell line, RoSH2 cell line.
We found that PI3 K/Akt/mTOR but not Raf/MEK/Erk sig-
naling was downregulated during differentiation. Inhibi-
tors of PI3 K/Akt/mTOR but not Raf/MEK/Erk signaling
reduced proliferation of RoSH cells and induced expres-
sion of endothelial specific proteins. Downregulation of
PI3 K/Akt/mTOR signaling during differentiation or treat-
ment with rapamycin, a specific inhibitor of mTOR was
associated with downregulation of mTOR-mediated
translational control. Ribosomal recruitment of 5' tract of
pyrimidines (TOP)-containing RNAs e.g. ribosomal pro-
tein L5 RNA transcripts was reduced. Transcript abun-
dance of cyclinD2, a G1 cyclin that promotes G1/S
progression was also reduced in ribosome-enriched RNA
fraction but not total RNA, accompanied by a correspond-
ing decrease in cyclin D2 protein level. In contrast, tran-
script abundance of endothelial specific proteins, Kdr (or
Flk1), Tek (or Tie2) and Pdgfrα was increased in ribos-
ome-enriched RNA fraction and protein levels were
increased.
Results
Proliferation rate of self-renewing RoSH2 cells was 
reduced when induced to differentiate
To determine if proliferation in RoSH-like cell was
reduced during differentiation, a representative embryo-
derived clonal RoSH line, RoSH2 cell line that is highly
similar to ESC-derived RoSH, E-RoSH cell lines was used
for this study [3,4]. The rate of cell division before and
after induction of differentiation was determined by pre-
labeling cells with cell-permeable CFDA fluorescent dye
[7] and the cells were then plated on either gelatin or
matrigel. The rate of cell division was calculated as a func-
tion of the loss in cellular fluorescence during a 24 hour
period (see method). Undifferentiated cells plated on gel-
atin maintained a constant rate of cell division from 2.08
± 0.02 to 2.13 ± 0.03 (n = 3) over a 72 hour period while
the rate of cell division in differentiating cells plated on
matrigel was significantly reduced from 2.08 ± 0.04 (n =
3) to 1.4 ± 0.05 (n = 3) divisions per 24 hours (p < 0.05)
(fig 1a). The reduced rate of cell division after induction
of differentiation was reflected in a 4-fold reduction in cell
population in the differentiating cell culture at 72 hours
(fig 1b).
PI3K/Akt and not Raf/MEK/Erk regulates proliferation of 
RoSH2 cells
To determine if PI3K/Akt and/or Raf/MEK/Erk signaling
regulate proliferation in self-renewing RoSH2 cells, the
cells were treated with LY294002 (a specific inhibitor of
PI3K), FTI (an inhibitor of Raf) and PD98059 (an inhibi-
tor of MEK) and the rate of cell division was measured. At
72 hours after treatment, the rate of cell division in
untreated, FTI and PD98059 treated RoSH2 cells were not
significantly different at 2.36 ± 0.09 (n = 3) 2.25 ± 0.12 (n
= 3) and 2.48 ± 0.16 (n = 3), respectively (fig 2a). How-
ever, the rate of cell division was significantly reduced to
0.90 ± 0.07 (n = 3) in LY294002 treated RoSH2 cells (p <
0.01) (fig 2a). 72 hours after drug treatment, cell popula-
tion size in FTI and PD98059 treated RoSH2 cell cultures
were comparable to that of untreated cells. LY294002
treated RoSH2 cell population was much reduced and was
23.9 ± 2.89% (n = 3) of untreated cultures. These observa-
tions suggested that PI3 K/Akt signaling and not Raf/MEK/
Erk is the major signaling pathway regulating prolifera-
tion in RoSH2 cells.
PI3 K/Akt mediates proliferation through a rapamycin-
sensitive pathway
We next determined if PI3 K/Akt regulates proliferation
through its downstream target, the mammalian target of
rapamycin (mTOR), a highly conserved serine/threonine
kinase and a major regulator of cell growth and prolifera-
tion [5]. Rapamycin is a specific inhibitor of mTOR [8]. At
50 nm, rapamycin significantly reduced the rate of cell
division in undifferentiating cells from 2.2 ± 0.09 (n = 4)
to 1.4 ± 0.04 (n = 4) (p < 0.05) in 24 hours (fig 3a). This
reduced rate was greater than the rate of 0.90 ± 0.07 (n =
3) elicited in LY294002 treated RoSH2 cells, suggesting
that a rapamycin-sensitive pathway partially mediates PI3
K regulation of cell division in undifferentiated RoSH
cells. Rapamycin treatment had no significant effect on
the rate of cell division in differentiating RoSH cell cul-
tures. 24 hours after treatment, the rate of cell division wasJournal of Molecular Signaling 2007, 2:9 http://www.jmolecularsignaling.com/content/2/1/9
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remained unchanged from 1.5 ± 0.22 (n = 4) to 1.5 ± 0.12
(n = 4) (fig 3a). Increasing the concentration of rapamycin
from 50 to 200 ηM had no significant effect on the rate of
cell division (data not shown). Therefore, differentiation-
associated decrease in cell division was mediated by
downregulation of a rapamycin-sensitive pathway, possi-
bly mTOR signaling such that further inhibition by
rapamycin elicited no further decrease in the rate of cell
division. As inhibition of mTOR signaling is known to
inhibit cell cycle through reduced G1/S progression
[9,10], dividing RoSH2 cells were labeled with BrdU and
the distribution of BrdU-labeled cells in different phases
of cell cycle was determined by DNA content. Undifferen-
tiated self-renewing cells maintained 34–35% of cells in
G1 phase (fig 3b). Rapamycin and differentiation induced
accumulation of cells in G1 phase. In 12 hours, there was
an increase from 34.25 ± 0.59% to 75.37 ± 0.26% (n = 3;
p < 0.05) in rapamycin-treated cells (fig 3b) and a slower
increase from 44.06 ± 0.44% to 54.47 ± 1.35% (n = 3; p <
0.05) in differentiating RoSH2 cells. The slower increase
in differentiating RoSH2 cells was not unexpected as the
inhibition of mTOR during differentiation unlike
rapamycin-induced inhibition will have to be effected
indirectly through a cascade of cellular events. Therefore
Effects of inhibiting PI3 K/PI3K/Akt or Raf/MEK/Erk on  growth of RoSH2 cells Figure 2
Effects of inhibiting PI3 K/PI3K/Akt or Raf/MEK/Erk 
on growth of RoSH2 cells. RoSH2 cells were pre-labeled 
with CFDA, cultured on gelatin-coated plates for 24 hours. 
One quarter of the plates were not treated with any inhibi-
tor (N), one quarter with 10 µM Ras inhibitor, FTase inhibi-
tor III (FTI), one quarter with 50 µM MEK inhibitor PD98059 
(PD), and the last quarter with LY 294002 (LY). Each of the 
media with the appropriate inhibitors was replaced every 
twenty-four hours. At 0, 24, 48 and 72 hours after plating, 
cells were harvested and were assayed for cellular fluores-
cence by flow cytometry. The number of cell cycles for every 
24 hours was calculated as described in Materials and Meth-
ods. b) Effects of FTI and PD98059 on cell numbers. Twenty-
four hours after treatment with FTI, PD98059 or a combina-
tion of both drugs, the cell numbers were counted and nor-
malized against that of untreated cells. Cell number at time 0 
was designated as one.
Growth and cell cycle regulation during endothelial differen- tiation Figure 1
Growth and cell cycle regulation during endothelial 
differentiation. a) Rate of cell proliferation. RoSH2 cells 
were labeled with CFDA, a cell-permeable fluorescent dye, 
and then cultured for 24 hours. They were then plated on 
gelatin-coated plates under non-differentiating condition or 
on matrigel-coated plate under differentiating condition. At 
0, 24, 48 and 72 after plating, cells were harvested, median 
cellular fluorescence was measured by flow cytometry and 
the number of cell divisions was calculated as a function of 
the loss in fluorescence for every twenty-four hour; b) the 
cell numbers were counted and normalized against cell count 
at time 0. Cell number at time 0 was designated as one.Journal of Molecular Signaling 2007, 2:9 http://www.jmolecularsignaling.com/content/2/1/9
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Growth and cell cycle regulation during endothelial differentiation and rapamycin treatment Figure 3
Growth and cell cycle regulation during endothelial differentiation and rapamycin treatment. a) Rate of cell divi-
sion. RoSH2 cells were labeled with CFDA, a cell-permeant fluorescent dye, cultured for 24 hours and re-plated on gelatin-
coated plates to be maintained as undifferentiated cells (Undif) or on matrigel to induce differentiation (Dif). Cells were har-
vested at 0, 24, 48 and 72 hours. At 48 hours after replating, half of the remaining plates of cells under undifferentiating condi-
tion or differentiating condition were treated with 50 ηM rapamycin (R undif and Rdif, respectively). Median cellular 
fluorescence of the harvested cells was measured by flow cytometry and the number of cell divisions was calculated as a func-
tion of the loss in fluorescence; b) Cell cycle progression during endothelial differentiation. RoSH2 cells were plated on either 
gelatin-coated plate (self-renewing) or matrigel (differentiating) and labeled with BrdU for 16 hours. After removing BrdU, half 
of the gelatin-coated plates were treated with 50 ηM rapamycin. At 0, 6 and 12 hours, cells were harvested, stained with anti-
BrdU and PI. DNA content of BrdU-labeled cells as measured by PI was analyzed by flow cytometry.
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rapamycin treatment and induction of differentiation elic-
ited similar cellular responses i.e. reduced cellular prolif-
eration and accumulation of dividing cells in G1 phase
suggesting that rapamycin-sensitive PI3K/Akt/mTOR is a
major signaling pathway in promoting proliferation of
undifferentiated RoSH2 cells and inhibiting differentia-
tion.
Downstream effectors of PI3 K/Akt/mTOR signaling, 
Rps6kb1 (or S6K1) and Eif4ebp1 (or 4EBP1) were 
dephosphorylated during differentiation of RoSH2 cells
To investigate the molecular mechanism of PI3 K/Akt/
mTOR in mediating proliferation, we determined the
phosphorylation status of the major downstream effector
molecules of PI3 K/Akt/mTOR signaling, eIF4E-binding
protein 1, Eif4ebp1 (previously known as PHAS-I and
mouse homolog of human 4EBP1) and the ribosomal
protein S6 kinase 1, Rps6kb1 (previously known as
p70s6k or S6K1) [5]. It is well established that rapamycin-
sensitive mTOR (or Frap1) activity regulate G1/S phase
progression in cell cycle through Rps6kb1 and Eif4ebp1
[9,11]. During differentiation of RoSH2 cells when the
level of endothelial specific markers such as Tek and Kdr
(fig 4a) were increasing, we observed a corresponding
decrease in phosphorylated Rps6kb1 and the ratio of
hyperphosphorylated β to hypophoshorylated α isoform
of Eif4ebp1 decreased (fig 4b). Consistent with this, treat-
ment of RoSH2 cells with rapamycin also inhibited phos-
phorylation of Rps6kb1 and Eif4ebp1 (fig 4c) and
unexpectedly increased expression of endothelial specific
proteins such as Tek and Kdr (fig 4d).
Phosphorylation of Rps6kb1 and Eif4ebp1 is mediated by 
PI3 K/Akt/mTOR and not Raf/MEK/Erk signaling
To confirm that PI3K/Akt signaling in RoSH2 cells was
transduced through mTOR, RoSH2 cells were serum-
starved and then challenged with insulin in the presence
of LY294002 and wortmannin. Both wortmannin and
LY294002 attenuated insulin-induced phosphorylation
of Akt and reduced phosphorylated Tsc2 levels (lane 4, 5;
fig 5a) relative to that in undifferentiated RoSH2 cells
(lane 1; fig 5a), in serum starved RoSH2 cells treated with
DMSO and insulin (lane 2; fig 5a) or in serum starved
RoSH2 cells treated with insulin (lane 3; fig 5a). As
unphosphorylated Tsc2 is known to inhibit mTOR [12],
our observed reduction in phosphorylated Tsc2 will result
in increased inhibition of mTOR. This was confirmed by
the reduced ratio of the highly phosphorylated γ and β
isoforms to the less phosphorylated α isoform of
Eif4ebp1 and reduced level of phospho-Rps6kb1 (lane 4,
5; fig 5a) relative to that in undifferentiated RoSH2 cells
(lane 1; fig 5a), in serum starved RoSH2 cells treated with
DMSO and insulin (lane 2; fig 5a) or in serum starved
RoSH2 cells treated with insulin (lane 3; fig 5a). In all
treatments, the level of Rps6kb1 was constant.
As the classical MAP kinase (Erk) pathway is sometime
implicated in the regulation of mTOR and downstream
effectors, Rps6kb1 and Eif4ebp1 [13-21], the level of
pERK1/2 was determined and found to be constant dur-
ing differentiation (fig 5b). Inhibition of Raf/MEK/Erk
pathway by treating cells with farnesyl transferase inhibi-
tor (FTI), a Ras inhibitor, or PD98059, a MEK inhibitor
abolished phosphorylation of pERK1/2 without signifi-
cant effects on phosphorylation of Eif4ebp1 or Rps6kb1.
These observations suggest that mTOR signaling in
RoSH2 cells is downstream of PI3 K/Akt and not Raf/
MEK/Erk pathway.
Rapamycin-sensitive translational regulation during 
differentiation
Eif4ebp1 and Rps6kb1 function primarily to promote
ribosomal recruitment of specific classes of mRNAs e.g.
TOP-containing mRNAs [22]. We therefore examined if
dephosphorylation of Eif4ebp1 and Rps6kb1 during dif-
ferentiation or rapamycin-treatment resulted in reduced
ribosomal recruitment of TOP containing mRNA or
mRNAs associated with G1/S progression in cell cycle or
endothelial differentiation. Total cellular extract and a cel-
lular fraction that was enriched 3–4 fold in ribosomes
were prepared from RoSH2 cells before and 48 hours after
differentiation or rapamycin treatment. Enrichment of
ribosomes was assessed by the relative increase in 18S and
28S ribosomal RNA (fig 6a). We observed that consistent
with the involvement of Eif4ebp1 and Rps6kb1 during
differentiation and rapamycin treatment, there was a con-
comitant displacement of a TOP containing mRNA, RNA
ribosomal protein L5 (Rpl5) RNA from the ribosome-
enriched fraction (fig 6b). There was no significant
decrease in total Rpl5 RNA abundance. We next investi-
gated if there were changes in ribosomal recruitment of
mRNAs associated with G1/S progression in cell cycle or
endothelial differentiation during differentiation and/or
rapamycin treatment. As cyclinD1, a member of the G1
cyclins that regulate G1/S transition [23-25] has previ-
ously been shown to be regulated at the translational level
through the PI3 K pathway [26,27], we examined the G1
cyclins consisting of cyclinD family of D1, D2 and D3 and
cyclinE family of E1 and E2. RoSH2 cells did not express
detectable levels of cyclinD1 transcript (fig 6c). Tran-
scripts of the remaining four cyclins, D2, D3, E1 and E2
were detectable and their total transcript abundance
remained unchanged during differentiation. However,
transcript abundance of cyclinD2 and cycinE1 in ribos-
ome-enriched RNA fraction was much reduced during dif-
ferentiation and there was a corresponding decrease in
their respective protein levels (fig 6d). We observed that in
contrast to cyclinD2 and E1, the transcript abundance of
several endothelial receptors e.g. Pdgfrα [28-30], Tek [31]
and Kdr [32] was either increased or not reduced in the
ribosome-enriched RNA fraction during differentiationJournal of Molecular Signaling 2007, 2:9 http://www.jmolecularsignaling.com/content/2/1/9
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(fig 6c; data not shown for Kdr) and their protein levels
were increased.(fig 6d). Rapamycin treatment induced a
similar response. Rpl5 and cyclinD2 transcript abundance
were reduced in the ribosome-associated RNA fraction
with similar reductions in their protein levels (fig 6e, f).
Transcript abundance of an endothelial specific receptor,
Tek was increased in the ribosome-associated RNA frac-
tion and protein level (fig 6e, f). Consistent with rapamy-
cin treatment, inhibiting PI3 K with either LY 294002or
wortmannin also decreased cyclinD2 and increased Tek
(fig 5a).
Discussion
We have previously derived lineage-restricted stem cell
lines from either embryos or ESCs as a strategy to circum-
vent some of the problems associated with the use of ESCs
for replacement therapy, namely the risk of tumor forma-
tion and the efficiency of generating clinically useful cell
types in large and homogenous quantity [3]. Towards this
end, we have derived clonal RoSH cell lines from mouse
embryos [4] and more recently, molecularly defined
CD9hi SSEA-1- E-RoSH cell lines from mouse ESCs [3].
RoSH and E-RoSH cell lines are highly similar with a
highly correlated genome-wide gene expression profile (r2
= 0.93) [3]. They can be propagated in an undifferentiated
state and can be induced to differentiate efficiently into
endothelial cells in vitro and in vivo. To better manipulate
these lines, we investigated the signaling process that reg-
ulates proliferation and differentiation of these lines.
We demonstrated that PI3 K/Akt/mTOR but not Raf/
MEK/Erk signaling was the critical signaling pathway in
the proliferation of undifferentiated RoSH cells. Inhibi-
tion of PI3 K/Akt/mTOR but not Raf/MEK/Erk signaling
reduced cellular proliferation, increased accumulation of
dividing cells in G1 phase, dephosphorylated Eif4ebp1
and Rps6kb1, abrogated ribosomal recruitment of specific
classes of mRNAs e.g. TOP mRNAs and cyclinD2 mRNA
and enhanced expression of endothelial receptors e.g.
Kdr, Tek, Pdgfrα [33]. Consistent with these observations,
PI3 K/Akt/mTOR but not Raf/MEK/Erk signaling was
reduced when self-renewing RoSH2 cells were induced to
differentiate. Differentiating RoSH2 cells manifested sim-
ilar molecular characteristics of rapamycin-treated cells.
The response was however generally more gradual than
that observed in rapamycin-treated cells, possibly because
inhibition of mTOR during differentiation was elicited
through a cascade of cellular events unlike direct inhibi-
tion by rapamycin.
The major downstream targets of PI3 K/Akt/mTOR-medi-
ated regulation are the major regulators of translational
Phosphorylation of mTOR targets and expression of endothelial markers during differentiation and rapamycin treatment Figure 4
Phosphorylation of mTOR targets and expression of endothelial markers during differentiation and rapamycin 
treatment. At 0, 6, 24 and 48 hours after RoSH2 cells were induced to differentiate by plating on matrigel-coated plates or 
treated with 50 ηM rapamycin, the cells were harvested for western blot analysis and probed for a, d) endothelial markers, 
Tie-2 and Flk-1; b, c) Eif4ebp1 and phosphorylated Rps6kb1. Tsc2 protein was used as an internal control for loading between 
lanes and between blots.Journal of Molecular Signaling 2007, 2:9 http://www.jmolecularsignaling.com/content/2/1/9
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control, Rps6kb1 and Eif4ebp1 [5]. Both Rps6kb1 and
Eif4ebp1 enhance translation of specific classes of mRNAs
e.g TOP-containing mRNAs that include Rpl5 mRNA [22].
They also regulate G1/S progression in the cell cycle
[9,11]. Here we demonstrated that in proliferating RoSH2
cells, Rps6kb1 and Eif4ebp1 were highly phosphorylated.
CyclinD2 and Rpl5 transcripts were associated with ribos-
omes, and cyclinD2 was easily detectable at the protein
level. When RoSH2 cells were induced to differentiate or
treated with rapamycin, Rps6kb1 and Eif4ebp1 became
dephosphorylated, and cyclinD2 transcripts were dis-
placed from ribosome-enriched RNA fraction without a
significant reduction in total RNA abundance and its pro-
tein product was significantly reduced. These observations
suggest that cyclinD2 expression in proliferating RoSH/E-
RoSH cells is maintained by active translation of its tran-
scripts by PI3 K/Akt/mTOR signaling, and upon differen-
tiation, its expression is downregulated through reduced
PI3 K/Akt/mTOR signaling that resulted in reduced trans-
lation. In contrast, translation of endothelial specific Pdg-
frα [28-30], Tek [31] and Kdr [32] transcripts were either
increased or not reduced during differentiation, and their
protein products were significantly increased, suggesting
that translation of these transcripts is not regulated by PI3
K/Akt/mTOR signaling.
CyclinD2 is a G1 cyclin that promotes G1/S progression
[23-25]. The association of translational regulation of
cyclinD2 with PI3K/Akt/mTOR signaling provided a
molecular basis for the downregulation of cell prolifera-
tion and inhibition of G1/S progression in cell cycle when
PI3K/AKt/mTOR signaling was inhibited in differentiat-
ing RoSH2 cells or during treatments with inhibitors of
PI3K/Akt/mTOR signaling. The increased protein level of
endothelial specific receptors during downregulation of
PI3K/Akt/mTOR signaling also provided a link between
the inhibition of proliferation and the induction of differ-
entiation. The rapid increase in protein levels of critical
angiogenic or vasculogenic receptors such as Kdr and Tek
[32] upon inhibition of proliferation in RoSH cells pro-
vided a molecular basis for the robust and efficient differ-
entiation of RoSH/E-RoSH cells into endothelial cells. As
previously reported, expression of these receptors on cell
surface was robustly induced with a dramatic increase
from <1% to >60% of the cells expressing either or both
receptors within 60 hours of differentiation [3]. However,
the role of PI3K/Akt/mTOR signaling in regulating the
PI3K and Raf/MEK/Erk signaling in RoSH2 cells Figure 5
PI3K and Raf/MEK/Erk signaling in RoSH2 cells. a) Effects of PI3 K/Akt inhibitors. Undifferentiated RoSH2 cells were 
plated and cultured for 24 hours, then serum-starved for 20 hours before culturing in media with 50 µM LY294002 dissolved in 
DMSO, 100 nM wortmannin or 0.1% (v/v) DMSO for 15 min and then challenged with 100 nM insulin for 20 minutes. Cell 
lysates were prepared and assayed by western blot analysis; b) Raf/MEK/Erk signaling during differentiation. At 0, 6, 24 and 48 
hours after plating RoSH2 cells on matrigel, cell lysates were prepared and analyzed by western blot assay for phosphorylated 
ERK1/2.. c) Effects of inhibiting Raf/MEK/Erk signalingRoSH2 cells were treated with 10 µM or 50 µM Ras inhibitor FTase inhib-
itor III, (FTI) and MEK inhibitor PD98059 for three hours and cell lysates were analyzed by western blot assays.Journal of Molecular Signaling 2007, 2:9 http://www.jmolecularsignaling.com/content/2/1/9
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protein level of these endothelial receptors is clearly
mechanistically different from that of cyclinD2.
Together, our observations in this study are consistent
with a general view that mTOR-mediated translation reg-
ulation is important in regulating proliferation and differ-
entiation of stem or progenitor cells including embryonic
stem cells [34], and adult stem cells such as vascular
smooth muscle progenitor cells [35], neural progenitor
cells [36] and liver cancer cells [37]. More specifically, our
observations are consistent with the view that a primary
cellular response to mitogenic PI3K/Akt signaling path-
way is the elicitation of differential translational regula-
tion of specific mRNA subsets via coordinated activation
Translational control during endothelial differentiation and rapamycin treatment Figure 6
Translational control during endothelial differentiation and rapamycin treatment. a) Preparation of total RNA and 
ribosome-enriched RNA. RoSH2 cells, RoSH2 induced to differentiate by plating on matrigel for 48 hours and RoSH2 cells 
treated with 50 ηM rapamycin for 48 hours were harvested. Total and ribosome-enriched RNAs were quantitated by absorb-
ance at 260 nm. 2 µg of RNA from each of the two cellular fractions were separated on a 1.0% agarose gel, stained with ethid-
ium bromide and visualized under UV illumination. Top panel Representative RNA samples from total and ribosome-enriched 
RNAs prepared from undifferentiated (Undiff), differentiated (Diff) and rapamycin-treated (Rapa) RoSH2 cells are shown. Bot-
tom panel For each sample, 1 µl of serially diluted RNA sample mixed with 1 µl of 0.5 ηg/µl ethidium bromide was visualized 
under UV illumination to verify RNA loading in each lane; RNA was isolated from total cellular extract (total) and ribosome-
enriched subcellular fraction (ribo) prepared from RoSH2 cells before and 48 hours after induction of endothelial differentia-
tion by plating matrigel-coated plates; b) Distribution of rpL5 mRNA in total and ribosome-enriched RNAs before and after dif-
ferentiation. RT-PCR using oligo-dT-primed cDNA, and Rpl5 and Fkbp12 specific primers was performed on 10 fold serial 
dilution i.e. 1×, 10× and 100× of RNAs.; c) RT-PCR analysis of transcript abundance in RoSH2 cells before and after differenti-
ation. RoSH2 cells were induced to undergo endothelial differentiation by plating on matrigel. Total and ribosome-enriched 
RNA were purified at 0 and 48 hours and analyzed by RT-PCR for transcript abundance of G1 cyclins and endothelial recep-
tors; d) Western blot analysis. RoSH2 cells were induced to undergo endothelial differentiation by plating on matrigel and at 0, 
6, 24 and 48 hours, cell lysates were prepared and assayed by western blot analysis. Tsc2 protein was used as an internal con-
trol for loading between lanes and between blots; e) Effect of rapamycin on Rpl5, cyclinD2 and Tek transcript abundance in 
total and ribosome-enriched RNA. Total and ribosome-enriched RNA were isolated from RoSH2 cells treated for 0 and 48 
hours with 50 ηM rapamycin treatment and analyzed by RT-PCR; f) Western blot analysis. Cell lysates from rapamycin-treated 
RoSH2 cells at 0, 6, 24 and 48 hours were assayed by western blot analysis for cyclinD2 and Tek. Tsc2 protein was used as an 
internal control for loading between lanes and between blots.Journal of Molecular Signaling 2007, 2:9 http://www.jmolecularsignaling.com/content/2/1/9
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and inactivation of the components of translational
machinery and the general translational repressors [38].
This study also demonstrates that downregulation of PI3
K/mTOR signaling constitutes part of the molecular pro-
gram necessary to elicit endothelial differentiation of
endothelial progenitor cells. This is consistent with an ear-
lier report that PI3 K is critical for survival, mitogenesis
and migration but not for differentiation of endothelial
cells [39], and with the observations that aberrations in
PI3K pathway are implicated in many aspects of tumor
angiogenesis [40]. More specifically, perturbations in
rapamycin-sensitive mTOR activity generally result in
abnormal vascularization (reviewed [41,42]). In particu-
lar, tsc1+/- or tsc2+/- mutant mice which are characterized
by high level of mTOR-mediated phosphorylation of
Eif4ebp1 and Rps6kb1, have hemangiomas with poorly
developed vasculature that are prone to rupture [43-45].
Therefore, our observation that downregulation of PI3 K/
mTOR signaling is a critical component in the prolifera-
tion and endothelial differentiation of RoSH2 endothelial
progenitor cells provides a mechanistic basis for abnor-
mal vascularization with functionally defective vascula-
ture when this pathway is constitutively active in
hamatomas [42]. We postulate that failure to downregu-
late PI3 K/mTOR signaling during endothelial differentia-
tion prevents endothelial progenitor cells from exiting
from cell cycle to properly initiate a differentiation pro-
gram, resulting in proliferation of abnormally differenti-
ated endothelial cells and formation of functionally
defective vasculature.
Conclusion
In conclusion, this study highlights the importance of
translation regulation as a critical regulatory mechanism
in the regulation of self-renewal and differentiation in
stem cells. As demonstrated here, PI3 K/Akt/mTOR-medi-
ated translation regulation was a dominant regulatory
mechanism in the proliferation and endothelial differen-
tiation of RoSH/E-RoSH cells. It was critical in maintain-
ing a high level of proliferation-associated proteins such
as cyclinD2 to drive cell cycle activity. Downregulation of
this signaling either during differentiation or through use
of small molecule inhibitors, inhibits translation of pro-
liferation-associated cyclinD2 gene transcripts but not dif-
ferentiation-associated markers.
Methods
Cell culture
The maintenance and differentiation of RoSH2 cells have
been previously described [4]. To test the effects of PI3 K
inhibitors, LY294002 and wortmannin on mTOR activity,
cells were cultured for 24 h immediately after passaging
and then deprived of serum for 20 h. Cells were then
treated with or without 50 µM LY294002 (Sigma, St.
Louis, MO) or 100 ηM wortmannin (Sigma, St. Louis,
MO) for 15 min and then stimulated with 100 ηM insulin
for 20 min. For other treatment, 80% confluent cultures
were treated with 50 ηM rapamycin (Sigma, St. Louis,
MO), 10 µM Ras inhibitor FTase inhibitor III (Calbio-
chen-Novabrochem Corp, La Jolla, CA) and 50 µM MEK
inhibitor PD98059 (Calbiochen-Novabrochem Corp, La
Jolla, CA).
Proliferation assay
To assess cell cycle rate, 2 × 108 RoSH2 cells were pre-
labeled with 2 ml of 10 µM CFDA (Molecular Probe,
Eugene, Or) in saline at 37°C for 15 minutes, cultured in
non-differentiating conditions for 24 hours and then
replated at 1 × 105 cells per 3 cm dish under non-differen-
tiating or differentiating conditions. For drug treatment,
the cells were cultured in the presence of 50 ηM rapamy-
cin, 50 µM LY294002, 10 µM Ras inhibitor FTase inhibi-
tor III, or 50 µM MEK inhibitor PD98059. For each drug,
the controls were treated with vehicle alone. At 0, 24 and
48 hours, three plates of cells were harvested, fixed in 2%
paraformaldehyde, and analyzed on a FACStarplus (Becton
Dickinson; San Jose, CA). The number of cell cycles per 24
hours was calculated assuming that each halving of cellu-
lar fluorescence represented one cell division. Therefore,
the number of cell cycles per 24 hours (n) was calculated
as n = (lg F/Fn)/lg 2 where F is initial average cellular fluo-
rescence and Fn is the average cellular fluorescence after 24
hours.
Cell cycle analysis using BrdU
RoSH2 cells were plated on gelatin or matrigel for 24
hours before they were labeled for 16 hours with 10 µM
BrdU (Sigma, St Louis). BrdU was then removed and fresh
medium was added and were cultured for another 6 or 12
hours. For rapamycin treatment, cells were cultured on
gelatin for 24 hours before pulse-labeling for 16 hours
with 10 µM BrdU (Sigma, St Louis) after which 50 ηM
rapamycin was added. Cells were fixed in ice cold 70%
ethanol, treated with 2 N HCl/0.1% Triton-100× in PBS
for 20 minutes at 37°C, and then incubated with FITC-
conjugated anti-BrdU antibody (Pharmingen,) at 1:50
dilution, 30 minutes at room temperature. Cells were
then counterstained with propidium iodide (10 µg/ml in
PBS) in the presence of 1 mg/ml RNaseA for 30 minutes
at room temperature and analyzed by flow cytometry.
Preparation of total cellular and ribosome-enriched RNA
Total RNA were prepared using a modified method of
Chomczynski and Sacchi as previously described [46,47].
Ribosomal RNA was prepared using a modified protocol
for preparing polysomes [48]. Briefly, exponentially grow-
ing cells were harvested and resuspended at 108 cells per
ml buffer (10 mM Tris-Cl, pH 7.6, 1 mM potassium ace-
tate, 1.5 mM magnesium acetate, 2 mM dithiothreitol
(DTT), 10% glycerol, 1 µg/ml leupeptin, 1 µg/ml pepsta-Journal of Molecular Signaling 2007, 2:9 http://www.jmolecularsignaling.com/content/2/1/9
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tin A, 100 µg/ml phenylmethylsulfonyl fluoride). Cells
were homogenized in a pre-chilled Dounce homogenizer
sitting in an ice-water bath and cell lysates were centri-
fuged at 9000 g for 10 minutes at 4°C. The resulting
supernatant was layered over a cushion of 30% (w/v)
sucrose in lysis buffer and centrifuged at 130,000 g for 2·5
hours at 2°C. The ribosomal RNA pellet was resuspended
in acid-guanidinium thiocyanate buffer and RNA was
purified using a CsCl gradient.
RT-PCR
RT-PCR was performed as previously described [4].
Primer sets for amplification of the following genes and
the expected amplified cDNA fragment size were a)
FKBP12 5'-CAC GGG GAT GCT TGA AGA TGG-3' and 5'-
GTC TAT ACA AAG GGT GGT GGG-3', 371 bp; b) PDG-
FRα 5'-CCA GTA GTT CCA CCT TCA TCA-3' and 5'-CAA
GTA TCC CAG CTA TCC ACA-3', 275 bp; c) Tek 5'-CTG
TTG GCG TTT CTG ATT ATG-3' and 5'-GGG TCT GTC TCT
AGC ACT CTG-3', 482 bp; d) rpL5 5'-GCC TTC ACT TGC
TAT CTG GAT-3' and 5'-CCT CTT CTT CTT CAC TTC TCT-
3', 375 bp; e) Cyclin D1 5'-GTG AGG GAA GAG GTG AAG
GTG-3' and 5'-GGT TTG GTT TTG CCC GTG GTG-3', 732
bp; f) cyclin D2 5'-GTA AGA TGC TTA CAG GAG AAC-3'
and 5'-CCT CAC CCT CTT CCC TTA CAC-3', 585 bp; g)
cyclin D3 5'-CGC AAT TGC AGC TTC T AG G TA-3' and 5'-
CAT CCG CAG ACA TAG AGC AGG-3', 381 bp; h) cyclin
E1 5'-CGC TGC TCT GCC TTC TTA CTG-3' and 5'-GTC
CTC GCT GCT TCT GCT TTG-3', 326 bp; i) cyclin E2 5'-
GAA ATC TAC GCT CCT AAA CTC-3' and 5'-GTG TTT TCC
TGG TGG TTT TTC-3', 603 bp.
Western blot analysis
Standard procedures were used [49]. Briefly, cells were
lysed in RIPA buffer, centrifuged at 14,000 rpm for 15
minutes at 4°C and the supernatant was stored in aliquots
at -70°C. 20 µg lysate was denatured, separated on 10 or
15% SDS-polyacrylamide gel and electro-blotted onto a
nitrocellulose membrane. The membrane was incubated
sequentially with a primary antibody, then either a HRP
conjugated-secondary antibody or a biotinylated second-
ary antibody followed by neutravidin-HRP, and finally, a
HRP enhanced chemiluminescent substrate, ECS (Pierce,
Rockford, IL). Each membrane was probed sequentially
with three primary antibodies. The membrane was
stripped using 2% SDS, 100 mM β-mercaptoethanol and
50 mM Tris (pH 6.8) between exposure to each primary
antibody. Primary antibodies were 1:200 dilution of rab-
bit anti-phosphoRps6kb1, Rps6kb1, Eif4ebp1, Tsc2,
phosphoAkt1, cyclinD1, cyclinD2, cyclinD3 and cyclinE1,
goat anti-cyclinE2 and anti-(4E-BP1) polyclonal antibod-
ies (Santa Cruz Biotechnology, CA), and 1:500 dilution of
anti-MAPK (p42/44) rabbit polyclonal antibody (Cell Sig-
naling Technology, MA), and rat anti-Kdr and rabbit anti-
Tek (PharMingen, MA). Secondary antibodies were HRP-
conjugated goat anti-rabbit, rabbit anti-goat and rabbit
anti-mouse. After exposure to three primary antibodies,
ach membrane probed with rabbit anti-Tsc2 as an internal
control for loading.
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